Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma

Delany, Anne M.

doi:10.4161/cbt.10.1.12452

Cited by 11 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we demonstrated that serum concentrations of bone sialoprotein (BSP) are elevated in a cohort of 132 patients who underwent radical tumor resection for pancreatic cancer and that high pre-operative BSP levels represent a significant marker for an unfavourable patients´ prognosis. These data do not only argue for a novel function of circulating BSP as a serum marker in pancreatic cancer but do also support a potential relevance of BSP in the pathogenesis of pancreatic cancer, as recently suggested for other members of the SIBLINGs- family 11,14,20,21 .…”

Section: Discussionsupporting

confidence: 83%

Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma

Loosen

Hoening

Puethe

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Patients with pancreatic adenocarcinoma (PDAC) still face a very limited prognosis. At early stage, surgical tumor resection might offer long-term survival but disease recurrence is common and the existing stratification algorithms are often unsuitable to identify patients who particularly benefit from surgery. Here, we investigated the potential role of bone sialoprotein (BSP) as a circulating marker in patients undergoing resection of PDAC. We used ELISA to determine serum concentrations of BSP in a cohort of 132 PDAC patients as well as 39 healthy controls. Circulating BSP levels were significantly higher in PDAC patients compared to healthy controls. Notably, elevated preoperative BSP levels above the ideal cut-off value of 4743 pg/ml turned out as a significant predictor for an impaired postoperative survival. The potential of preoperative BSP levels as a prognostic marker was further underlined by uni- and multivariate Cox-regression analyses including various tumour- and patient-specific. Finally, high tumoral BSP expression was also associated with a significantly impaired long-term survival. In conclusion, we identified a novel role of circulating BSP as a biomarker in PDAC patients undergoing tumor resection. Such data might help to establish new preoperative stratification strategies to better identify patients who particularly benefit from tumor resection.

show abstract

Section: Discussionsupporting

confidence: 83%

Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma

Loosen

Hoening

Puethe

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Pancreatic ductal adenocarcinoma (PDAC) is among the malignancies with the worst prognosis. Increased expression of OPN mRNA was found in the tumor cells correlating with increased proliferation and malignant phenotype (Delany, 2010). Nicotine, a risk factor in PDAC, induces an alpha7-nicotine acetylcholine receptor (α7-nAChR)-mediated increase of OPN in PDAC cells.…”

Section: Opn Impacts Pathophysiologies Of Multiple Malignanciesmentioning

confidence: 99%

Role of osteopontin in the pathophysiology of cancer

2014

View full text Add to dashboard Cite

Osteopontin (OPN) is a multifunctional cytokine that impacts cell proliferation, survival, drug resistance, invasion, and stem like behavior. Due to its critical involvement in regulating cellular functions, its aberrant expression and/or splicing is functionally responsible for undesirable alterations in disease pathologies, specifically cancer. It is implicated in promoting invasive and metastatic progression of many carcinomas. Due to its autocrine and paracrine activities OPN has been shown to be a crucial mediator of cellular cross talk and an influential factor in the tumor microenvironment. OPN has been implicated as a prognostic and diagnostic marker for several cancer types. It has also been explored as a possible target for treatment. In this article we hope to provide a broad perspective on the importance of OPN in the pathophysiology of cancer.

show abstract

“…89 Expression of SPARC by stromal fibroblasts may be a generic indicator of an activated fibroblast phenotype or may influence pericyte migration, collagen deposition, and ultimately facilitate development of dense collagenous stroma. [89][90][91] More recently, SPARC has emerged as a potential biomarker in pancreatic cancer. Nab-paclitaxel was previously shown to have antitumor activity in various types of cancer that overexpress SPARC.…”

Section: Sparc and Nab-paclitaxelmentioning

confidence: 99%

Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel

Fontana¹,

Sclafani²,

Cunningham³

2014

GICTT

View full text Add to dashboard Cite

The management of pancreatic cancer has historically represented a major challenge for oncologists. The inherent aggressiveness of this tumor and the fibrotic features of the surrounding stromal tissue have significantly limited the impact of standard chemotherapy. Moreover, the paucity of available tumor tissue has hampered a better understanding of the biology of this disease as well as the development of new treatment strategies. Recently, the therapeutic landscape of metastatic pancreatic cancer has been enriched by two new combination regimens (FOLFIRINOX and gemcitabine-nab-paclitaxel) which have been demonstrated to improve the outcome in patients with good performance status. Moreover, the peritumoral stroma has been increasingly recognized as a potential therapeutic target for this disease, and several new agents targeting stromal components are currently under investigation. In this paper, we review the current treatment options for advanced pancreatic cancer, highlight the role of the peritumoral stroma, and discuss the clinical potential of nab-paclitaxel and antistromal treatment strategies.

show abstract

Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma

Cited by 11 publications

References 21 publications

Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma

Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma

Role of osteopontin in the pathophysiology of cancer

Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel

Contact Info

Product

Resources

About